ProfileGDS5678 / 1440354_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 48% 48% 47% 47% 51% 49% 48% 51% 47% 48% 47% 60% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2483950
GSM967853U87-EV human glioblastoma xenograft - Control 23.1361148
GSM967854U87-EV human glioblastoma xenograft - Control 33.1265348
GSM967855U87-EV human glioblastoma xenograft - Control 43.0393747
GSM967856U87-EV human glioblastoma xenograft - Control 53.046847
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3159451
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2409249
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1262948
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.222951
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0939747
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1430148
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0669747
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5853660
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1487749